Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In 2000, seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in the USA and resulted in dramatic reductions in invasive pneumococcal disease (IPD) and moderate increases in non-PCV7 type IPD. In 2010, PCV13 replaced PCV7 in the US immunisation schedule. We aimed to assess the effect of use of PCV13 in children on IPD in children and adults in the USA.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Infect Dis

Title: The Lancet. Infectious diseases

ISSN (Electronic): 1474-4457

ISSN (Print): 1473-3099

Publication date (Electronic): Mar 2015

Volume: 15

Issue: 3

Affiliations

[1 ] National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: matt.moore@cdc.hhs.gov.

[2 ] National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

[3 ] Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.

[4 ] Minnesota Department of Health, St Paul, MN, USA.

[5 ] Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

[6 ] Connecticut Department of Public Health, Hartford, CT, USA.

[7 ] New York State Department of Health, Albany, NY, USA.

[8 ] Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

[9 ] California Emerging Infections Program, Oakland, CA, USA; School of Public Health, Department of Epidemiology, University of California, Berkeley, CA, USA.

[10 ] Colorado Department of Public Health and Environment, Denver, CO, USA.

[11 ] Institute for Public Health, University of New Mexico, Emerging Infections Program, Albuquerque, NM, USA.

[12 ] Oregon Public Health Division and Oregon Emerging Infections Program, Portland, OR, USA.

[13 ] Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA; Infection Disease Section, Medical Specialty Care Service Line, Atlanta VA Medical Center, Atlanta, GA, USA.

[14 ] National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Stat-Epi Associates, Ponte Vedra Beach, FL, USA.

[15 ] Department of Pathology, University of Texas Health Science Center, San Antonio, TX, USA.

Article

Publisher Item ID: S1473-3099(14)71081-3 Mid ID: HHSPA787116

DOI: 10.1016/S1473-3099(14)71081-3

PubMed ID: 25656600

SO-VID: 6b18e022-d1fe-4816-9ec4-2ec172acb95d

History

Data availability:

Comments

Comment on this article

scite_

Cited by 269

See all cited by

- Version 1